<DOC>
	<DOCNO>NCT00889473</DOCNO>
	<brief_summary>This study look one dose AT1001 efficacy safety treatment celiac disease . The primary efficacy outcome rate response gluten .</brief_summary>
	<brief_title>Study Efficacy AT1001 ( Larazotide Acetate ) Treat Celiac Disease</brief_title>
	<detailed_description>This outpatient , randomize , double-blind multicenter study . Subjects remain gluten-free diet throughout duration trial . Study drug drug placebo capsule administer TID 15 minute meal ( breakfast , lunch , dinner ) . Gluten gluten placebo capsule take TID meal .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>1 . Age 18 72 year , inclusive 2 . Diagnosed Celiac Disease 12 month 3 . Antitissue Transglutaminase ( antitTG ) less 10 EU 4 . On glutenfree diet least 12 month 5 . BMI 18.5 38 , inclusive 1 . Current smoker 2 . Has chronic active GI disease Celiac Disease ( e.g. , Crohn 's , colitis ) 3 . Has diabetes ( Type 1 Type 2 ) 4 . Participated clinical drug study within past 30 day previous exposure AT1001 5 . Presents history dermatitis herpetiformis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Celiac Disease</keyword>
	<keyword>Gluten</keyword>
</DOC>